Matthias Tyssen joined Fresenius Kabi in 2014, currently heading portfolio and project management, product development, strategic marketing, regulatory and medical affairs as well as alliance management for the generic drug and I.V. fluids portfolio of outside of North America.  In this role Matthias is responsible for the development pipeline, maintenance of the product portfolio and product management of a 1.7 bn Euro business. The portfolio ranges from anti-Infectives, analgesics, oncology and critical care products to infusion solutions. Previously, he was responsible for the global parenteral nutrition portfolio and headed the business unit for infusion and irrigation solutions.

Matthias has a master in business and engineering from University of Stuttgart and a doctorate in strategic management from EBS Business School, Oestrich-Winkel.